Adipopharma
Strasbourg, FR · 2 known investors
Find your way into Adipopharma
180 people in our graph share verified history with the Adipopharma team — schools, employers, funds. One of them is your warm intro.
Adamunlockedknows Michael J. Fare · together at Drexel University
×3knows the team · via Saint Joseph's University
×8knows the team · via Drexel University
AdipoPharma is a biotech company developing therapies based on the endocrine biology of adipose tissue and targeted rare genetic disorders. Founded in 2022 (formerly ALMS Therapeutics), its work relates to metabolic diseases such as diabetes and obesity.
Founders & leadership
VM
Vincent MarioninFounder
CP
Catherine PerotinChief Financial Officer
MJ
Michael J. FareinChief Operating OfficerMichael J. Fare is Chief Operating Officer of AdipoPharma, a biotech company developing therapies for metabolic and rare genetic disorders. He has held roles in drug discovery and development, project management, and business development, including positions at Wyeth-Ayerst where he worked on pharmaceutical marketing and international business development.
TG
Tarekegn G. HiwotChief Medical Officer
Investors · 2
Frequently asked questions
- What does Adipopharma do?
- AdipoPharma is a biotech company developing therapies based on the endocrine biology of adipose tissue and targeted rare genetic disorders. Founded in 2022 (formerly ALMS Therapeutics), its work relates to metabolic diseases such as diabetes and obesity.
- Who founded Adipopharma?
- Adipopharma was founded by Vincent Marion.
- Who are Adipopharma's investors?
- Adipopharma's investors include Good Growth Capital, Newton Biocapital.
- Where is Adipopharma headquartered?
- Adipopharma is headquartered in Strasbourg, FR.